Denali Therapeutics now knows what it needs to do to get its Alzheimer’s disease drug DNL919 back on track. Almost one month after the FDA informed Denali of a clinical hold via email, the agency has ...
Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the company to mull the asset’s future. The therapy, dubbed DNL343, is designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback